



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2022





© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

December 2022

N = 7554



Health Authority	Male	Female	All
FRASER	1496	453	1949
INTERIOR	454	116	570
NORTHERN	153	81	234
VANCOUVER COASTAL	3320	442	3762
VANCOUVER ISLAND	832	168	1000
	6255	1260	7515
		Unknown/not stated:	39
		Total:	7554

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2017 - December 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2017 - December 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (December 2017 - December 2022)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (December 2017 - December 2022)






1.6 Percent Distribution of Active Participants by CD4 Count
(December 2017 - December 2022)






1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2017 - December 2022)






1.8 Active and Inactive Participants (December 2017 - December 2022)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2017 - December 2022)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2017 - December 2022)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2017 - December 2022)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2017 - December 2022)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2017 - December 2022)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2017 - December 2022)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2017 - December 2022)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2017 - December 2022)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(December 2017 - December 2022)






1.18 Baseline CD4 for Antiretroviral First Starts
(January 2018 - January 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (December 2017 - December 2022)






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2017 - December 2022)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2017 - December 2022)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	31	4	0	4	1	920	4	<40	4
1988	32	5	0	5	2	345	5	<40	3
1989	29	49	1	50	20	520	47	<40	3
1990	28	53	1	54	32	530	50	<40	3
1991	28	37	3	40	15	520	37	<40	3
1992	28	55	5	60	18	660	56	<40	3
1993	27	121	13	134	76	510	123	<40	3
1994	26	68	11	79	47	460	73	<40	3
1995	26	117	19	136	72	575	127	<40	3
1996	24	307	49	356	197	570	326	<40	3
1997	22	259	30	289	158	600	263	<40	3
1998	21	180	38	218	130	560	193	<40	3
1999	21	150	39	189	118	575	174	<40	3
2000	21	116	30	146	86	625	138	<40	3
2001	21	110	26	136	77	560	121	<40	3
2002	20	120	25	145	81	530	126	<40	3
2003	19	132	26	158	90	585	143	<40	3
2004	18	144	37	181	103	630	161	<40	3
2005	17	176	40	216	126	635	191	<40	3
2006	16	166	41	207	127	600	189	<40	3
2007	15	222	42	264	160	660	236	<40	3
2008	14	269	61	330	223	640	309	<40	3
2009	13	291	59	350	213	650	318	<40	3
2010	12	253	66	319	192	670	276	<40	3
2011	11	319	69	388	241	690	341	<40	3
2012	10	260	61	321	190	685	289	<40	3
2013	9	245	66	311	185	680	271	<40	3
2014	8	268	47	315	183	730	278	<40	3
2015	7	262	42	304	188	672	276	<40	3
2016	6	246	50	296	188	675	268	<40	3
2017	5	206	33	239	149	680	206	<40	3
2018	4	182	46	228	139	690	206	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	3	224	43	267	185	690	240	<40	3
2020	3	181	52	233	162	700	210	<40	3
2021	2	196	35	231	136	580	211	<40	3
2022	0	272	55	327	254	620	305	<40	3
Total:		6265	1261	7526					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	7384	746	1942	<40	1393	630
FEB-2021	7377	748	1787	<40	1276	630
MAR-2021	7432	743	2015	<40	1429	620
APR-2021	7417	746	1828	<40	1324	636
MAY-2021	7452	742	1868	<40	1306	630
JUN-2021	7456	738	1880	<40	1355	610
JUL-2021	7460	744	1820	<40	1348	640
AUG-2021	7465	741	1981	<40	1354	630
SEP-2021	7432	750	1763	<40	1248	630
OCT-2021	7432	755	1855	<40	1294	630
NOV-2021	7446	750	2021	<40	1379	630
DEC-2021	7462	757	1543	<40	1043	630
JAN-2022	7465	756	1878	<40	1316	650
FEB-2022	7386	774	1803	<40	1262	620
MAR-2022	7458	766	1904	<40	1250	620
APR-2022	7420	778	1755	<40	1150	620
MAY-2022	7477	763	1998	<40	1304	620
JUN-2022	7482	759	1839	<40	1197	630
JUL-2022	7495	755	1761	<40	1137	645
AUG-2022	7494	758	1990	<40	1221	620
SEP-2022	7445	771	1788	<40	1079	640
OCT-2022	7472	778	1849	<40	1151	640
NOV-2022	7513	783	1900	<40	1178	630
DEC-2022	7554	787	1605	<40	968	635

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	772	197	72	<40	55	540
FEB-2021	784	197	69	<40	56	510
MAR-2021	768	248	89	<40	71	630
APR-2021	801	255	73	<40	58	615
MAY-2021	778	273	73	<40	66	540
JUN-2021	776	261	65	57	49	540
JUL-2021	777	273	52	102	37	530
AUG-2021	783	262	53	<40	44	625
SEP-2021	827	227	64	<40	41	610
OCT-2021	830	240	79	<40	60	540
NOV-2021	814	260	78	<40	61	450
DEC-2021	794	245	48	<40	32	385
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	775	334	60	<40	43	490
JUN-2022	778	317	61	<40	43	400
JUL-2022	782	300	61	<50	35	453
AUG-2022	803	280	59	78	47	560
SEP-2022	859	228	70	<40	52	440
OCT-2022	841	232	83	<40	61	500
NOV-2022	821	246	78	68	55	490
DEC-2022	788	271	59	<40	43	560

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2021	7358	772	14	9	205	159	37	14209
FEB-2021	7351	784	15	13	186	189	-7	14233
MAR-2021	7404	768	15	24	203	156	53	14270
APR-2021	7390	801	13	9	165	172	-14	14295
MAY-2021	7418	778	14	14	177	143	28	14324
JUN-2021	7435	776	7	15	186	174	17	14350
JUL-2021	7438	777	9	12	170	166	3	14370
AUG-2021	7436	783	16	12	174	167	-2	14392
SEP-2021	7399	827	14	9	173	199	-37	14422
OCT-2021	7392	830	17	6	186	174	-7	14445
NOV-2021	7417	814	11	15	199	175	25	14471
DEC-2021	7430	794	22	6	204	174	13	14489
JAN-2022	7432	786	19	7	161	144	2	14504
FEB-2022	7371	856	8	9	151	211	-61	14529
MAR-2022	7432	800	16	9	232	160	61	14558
APR-2022	7397	834	11	1	156	178	-35	14578
MAY-2022	7450	775	13	13	205	146	53	14602
JUN-2022	7457	778	11	15	178	170	7	14639
JUL-2022	7469	782	10	13	188	176	12	14678
AUG-2022	7470	803	15	17	169	170	1	14716
SEP-2022	7426	859	13	15	146	190	-44	14744
OCT-2022	7450	841	14	17	195	170	24	14779
NOV-2022	7495	821	9	17	213	174	45	14818
DEC-2022	7526	788	19	8	210	165	31	14845

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6653	448	51	7378	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6670	463	51	7433	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6640	465	48	7452	4.01%	89.10%	6.24%	0.64%	100.00%
JUN-2021	326	6613	471	46	7456	4.37%	88.69%	6.32%	0.62%	100.00%
JUL-2021	354	6590	470	46	7460	4.75%	88.34%	6.30%	0.62%	100.00%
AUG-2021	381	6571	471	42	7465	5.10%	88.02%	6.31%	0.56%	100.00%
SEP-2021	398	6525	462	47	7432	5.36%	87.80%	6.22%	0.63%	100.00%
OCT-2021	409	6517	460	46	7432	5.50%	87.69%	6.19%	0.62%	100.00%
NOV-2021	438	6507	457	44	7446	5.88%	87.39%	6.14%	0.59%	100.00%
DEC-2021	468	6492	457	45	7462	6.27%	87.00%	6.12%	0.60%	100.00%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	445	45	7495	8.46%	85.00%	5.94%	0.60%	100.00%
AUG-2022	643	6367	441	43	7494	8.58%	84.96%	5.88%	0.57%	100.00%
SEP-2022	663	6298	439	45	7445	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6313	439	41	7472	9.09%	84.49%	5.88%	0.55%	100.00%
NOV-2022	696	6329	446	42	7513	9.26%	84.24%	5.94%	0.56%	100.00%
DEC-2022	709	6354	449	42	7554	9.39%	84.11%	5.94%	0.56%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	2 10%	3153 44%	1 5%	2880 40%	0 0%	28 0%	12 60%	2220 31%	6 30%	1962 27%	18 90%	4045 56%
FEB-2021	2 8%	3135 43%	2 8%	2843 39%	0 0%	27 0%	16 67%	2298 32%	6 25%	1899 26%	22 92%	4061 56%
MAR-2021	8 22%	3140 43%	7 19%	2832 39%	0 0%	24 0%	23 62%	2368 33%	6 16%	1858 26%	29 78%	4111 57%
APR-2021	2 8%	3137 43%	2 8%	2802 39%	0 0%	25 0%	17 68%	2422 33%	6 24%	1791 25%	23 92%	4104 57%
MAY-2021	7 24%	3150 43%	3 10%	2784 38%	0 0%	22 0%	15 52%	2497 34%	10 34%	1759 24%	22 76%	4131 57%
JUN-2021	4 15%	3137 43%	3 12%	2741 38%	0 0%	23 0%	17 65%	2574 35%	5 19%	1698 23%	22 85%	4153 57%
JUL-2021	3 15%	3126 43%	2 10%	2707 37%	0 0%	23 0%	13 65%	2626 36%	4 20%	1655 23%	17 85%	4166 57%
AUG-2021	1 5%	3109 43%	1 5%	2667 37%	0 0%	23 0%	16 73%	2660 36%	5 23%	1631 22%	21 95%	4182 57%
SEP-2021	4 13%	3078 42%	2 7%	2614 36%	1 3%	22 0%	21 70%	2707 37%	5 17%	1587 22%	26 87%	4178 57%
OCT-2021	5 22%	3082 42%	5 22%	2591 36%	0 0%	20 0%	13 57%	2755 38%	5 22%	1563 21%	18 78%	4196 58%
NOV-2021	3 12%	3071 42%	2 8%	2552 35%	0 0%	19 0%	18 72%	2812 39%	4 16%	1535 21%	22 88%	4216 58%
DEC-2021	3 18%	3067 42%	1 6%	2514 34%	0 0%	19 0%	10 59%	2861 39%	5 29%	1503 21%	14 82%	4237 58%
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2992 41%	4 11%	2262 31%	0 0%	18 0%	29 78%	3271 44%	3 8%	1179 16%	32 86%	4354 59%
SEP-2022	4 14%	2954 40%	3 11%	2197 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1174 16%	24 86%	4353 60%
OCT-2022	6 17%	2952 40%	4 11%	2175 30%	0 0%	16 0%	29 83%	3351 46%	0 0%	1144 16%	29 83%	4390 60%
NOV-2022	7 18%	2952 40%	5 13%	2162 29%	0 0%	15 0%	26 68%	3390 46%	6 16%	1140 15%	31 82%	4424 60%
DEC-2022	4 15%	2954 40%	3 11%	2151 29%	1 4%	16 0%	18 67%	3448 47%	5 19%	1114 15%	23 85%	4452 60%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	547 30%	2 100%	1205 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	536 30%	2 100%	1184 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	515 29%	3 100%	1183 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	508 29%	3 75%	1171 68%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2021	0 0%	1 0%	0 0%	492 29%	2 100%	1152 68%	0 0%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	386 26%	1 100%	1028 70%	0 0%	45 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	368 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	355 25%	0 0%	1003 72%	0 0%	44 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	998 72%	0 0%	43 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	341 24%	1 100%	1010 72%	0 0%	45 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	142 13%	0 0%	318 28%	2 67%	244 21%
DEC-2021	0 0%	98 9%	3 75%	340 30%	0 0%	134 12%	0 0%	316 28%	1 25%	243 22%
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	272 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	183 18%	2 67%	262 26%	0 0%	108 11%	0 0%	269 26%	0 0%	197 19%
DEC-2022	0 0%	186 19%	1 25%	255 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir													
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All												
JAN-2021	12	80%	1697	34%	3	20%	2461	49%	0	0%	442	9%	0	0%	0	0%	27	1%	0	0%	469	9%		
FEB-2021	14	64%	1774	35%	5	23%	2476	49%	3	14%	420	8%	0	0%	0	0%	0	0%	24	0%	0	0%	457	9%
MAR-2021	23	72%	1839	35%	9	28%	2491	48%	0	0%	418	8%	0	0%	0	0%	0	0%	24	0%	0	0%	454	9%
APR-2021	15	75%	1901	36%	4	20%	2504	48%	1	5%	412	8%	0	0%	0	0%	0	0%	22	0%	0	0%	438	8%
MAY-2021	15	65%	1979	37%	7	30%	2509	47%	0	0%	397	7%	0	0%	0	0%	0	0%	22	0%	1	4%	439	8%
JUN-2021	16	76%	2056	38%	4	19%	2498	47%	1	5%	387	7%	0	0%	0	0%	0	0%	23	0%	0	0%	440	8%
JUL-2021	13	81%	2111	39%	3	19%	2498	46%	0	0%	382	7%	0	0%	0	0%	0	0%	23	0%	0	0%	432	8%
AUG-2021	15	71%	2150	40%	5	24%	2488	46%	1	5%	374	7%	0	0%	0	0%	0	0%	23	0%	0	0%	424	8%
SEP-2021	18	72%	2192	40%	5	20%	2470	46%	2	8%	366	7%	0	0%	0	0%	0	0%	23	0%	0	0%	411	8%
OCT-2021	11	73%	2234	41%	3	20%	2469	45%	1	7%	363	7%	0	0%	0	0%	0	0%	24	0%	0	0%	398	7%
NOV-2021	17	77%	2303	42%	4	18%	2459	45%	1	5%	348	6%	0	0%	0	0%	0	0%	24	0%	0	0%	393	7%
DEC-2021	8	57%	2348	42%	5	36%	2463	45%	1	7%	349	6%	0	0%	0	0%	0	0%	24	0%	0	0%	380	7%
JAN-2022	11	73%	2421	43%	2	13%	2468	44%	1	7%	347	6%	0	0%	0	0%	0	0%	24	0%	1	7%	374	7%
FEB-2022	15	71%	2443	44%	6	29%	2437	44%	0	0%	331	6%	0	0%	0	0%	0	0%	21	0%	0	0%	369	7%
MAR-2022	23	85%	2536	45%	3	11%	2460	43%	1	4%	324	6%	0	0%	0	0%	0	0%	21	0%	0	0%	370	7%
APR-2022	14	74%	2574	45%	5	26%	2436	43%	0	0%	312	5%	0	0%	0	0%	0	0%	20	0%	0	0%	366	6%
MAY-2022	17	77%	2666	46%	5	23%	2455	43%	0	0%	309	5%	0	0%	0	0%	0	0%	22	0%	0	0%	360	6%
JUN-2022	29	85%	2710	47%	5	15%	2454	42%	0	0%	300	5%	0	0%	0	0%	0	0%	22	0%	0	0%	352	6%
JUL-2022	24	69%	2745	47%	7	20%	2452	42%	3	9%	297	5%	0	0%	0	0%	0	0%	22	0%	1	3%	342	6%
AUG-2022	26	76%	2790	48%	6	18%	2453	42%	1	3%	294	5%	0	0%	0	0%	1	3%	22	0%	1	3%	340	6%
SEP-2022	19	76%	2820	48%	6	24%	2434	42%	0	0%	281	5%	0	0%	0	0%	0	0%	21	0%	0	0%	323	6%
OCT-2022	28	80%	2889	49%	6	17%	2442	41%	1	3%	280	5%	0	0%	0	0%	0	0%	22	0%	0	0%	314	5%
NOV-2022	24	73%	2922	49%	8	24%	2467	41%	1	3%	276	5%	0	0%	1	0%	0	0%	22	0%	0	0%	309	5%
DEC-2022	16	70%	2976	49%	5	22%	2469	41%	1	4%	270	4%	0	0%	1	0%	0	0%	20	0%	1	4%	308	5%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1233	16.71	894	12.12	4226	57.28	223	3.02	689	9.34	113	1.53
MAR-2021	1210	16.28	890	11.97	4274	57.50	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4383	58.75	352	4.72	702	9.41	99	1.33
AUG-2021	1090	14.60	817	10.94	4384	58.73	377	5.05	700	9.38	97	1.30
SEP-2021	1070	14.40	812	10.93	4370	58.80	394	5.30	694	9.34	92	1.24
OCT-2021	1053	14.17	809	10.89	4387	59.03	406	5.46	685	9.22	92	1.24
NOV-2021	1038	13.94	804	10.80	4395	59.02	435	5.84	682	9.16	92	1.24
DEC-2021	1020	13.67	790	10.59	4416	59.18	464	6.22	682	9.14	90	1.21
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	829	11.06	691	9.22	4611	61.53	641	8.55	648	8.65	74	0.99
SEP-2022	800	10.75	692	9.29	4576	61.46	662	8.89	641	8.61	74	0.99
OCT-2022	790	10.57	673	9.01	4622	61.86	678	9.07	636	8.51	73	0.98
NOV-2022	773	10.29	683	9.09	4646	61.84	694	9.24	645	8.59	72	0.96
DEC-2022	775	10.26	664	8.79	4688	62.06	706	9.35	650	8.60	71	0.94

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	3	2	2	3	210
DEC-2021	6	1	1	1	3	0	350
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	17	0	0	1	5	10	525
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2021	12384	3834
FEB-2021	12377	3829
MAR-2021	12377	3820
APR-2021	12366	3807
MAY-2021	12361	3795
JUN-2021	12362	3789
JUL-2021	12383	3808
AUG-2021	12379	3816
SEP-2021	12348	3784
OCT-2021	12335	3776
NOV-2021	12339	3768
DEC-2021	12319	3762
JAN-2022	12306	3762
FEB-2022	12330	3777
MAR-2022	12359	3793
APR-2022	12388	3818
MAY-2022	12379	3807
JUN-2022	12394	3809
JUL-2022	12420	3818
AUG-2022	12441	3830
SEP-2022	12460	3839
OCT-2022	12487	3860
NOV-2022	12494	3849
DEC-2022	12473	3833

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7554
Dec-2022

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2022

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2022

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2022

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2022

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2022

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	44	60	24
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	78	105	60	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	427	580	320	
THOMPSON/CARIBOO/ SHUSWAP	20-34	24	24	15
	35-49	62	66	42
	50+	134	209	109
	Total HSDA:	220	299	166
Total HA:		769	1044	570

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		769	1044	570

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	158	216	116
Male	611	828	454

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	570	57	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	23	12
	5 years or more	13	6
	<5 years	8	6
	Total HSDA:	44	24
KOOTENAY BOUNDARY	10 years or more	47	31
	5 years or more	16	14
	<5 years	15	15
	Total HSDA:	78	60
OKANAGAN	10 years or more	276	201
	5 years or more	83	63
	<5 years	68	56
	Total HSDA:	427	320
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	140	108
	5 years or more	45	32
	<5 years	35	26
	Total HSDA:	220	166
Total HA:		769	570

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	486	352
5 years or more	157	115
<5 years	126	103
Total HA:	769	570

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	11	20
KOOTENAY BOUNDARY	77	137	22	49
OKANAGAN	235	1060	49	345
THOMPSON/CARIBOO/SHUSWAP	149	557	35	136
Total:	512	1824	117	550

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	5
KOOTENAY BOUNDARY	12
OKANAGAN	59
THOMPSON/CARIBOO/SHUSWAP	41
Total:	117

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	38	40	31
	35-49	99	103	69
	50+	258	357	189
	Total HSDA:	402	507	296
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1136	1535	851
FRASER SOUTH	0-19	8	8	8
	20-34	100	102	72
	35-49	293	321	228
	50+	617	937	494
	Total HSDA:	1018	1368	802
Total HA:		2556	3410	1949

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	16	16	16
	20-34	260	264	181
	35-49	755	813	579
	50+	1525	2317	1173
Total HA:		2556	3410	1949

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	618	789	453
Male	1938	2621	1496

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1949	53	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	259	195
	5 years or more	75	47
	<5 years	68	54
	Total HSDA:	402	296
FRASER NORTH	10 years or more	715	514
	5 years or more	237	186
	<5 years	184	151
	Total HSDA:	1136	851
FRASER SOUTH	10 years or more	636	487
	5 years or more	215	168
	<5 years	167	147
	Total HSDA:	1018	802
Total HA:		2556	1949

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1610	1196
	5 years or more	527	401
	<5 years	419	352
Total HA:		2556	1949

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	145	531	30	63
FRASER NORTH	258	1606	40	218
FRASER SOUTH	227	1773	49	483
Total:	630	3910	119	764

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	196
FRASER NORTH	702
FRASER SOUTH	456
Total:	1354

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		350	518
RICHMOND	20-34	32	33	20
	35-49	51	52	43
	50+	118	173	100
	Total HSDA:	201	258	163
VANCOUVER	0-19	12	12	11
	20-34	441	455	289
	35-49	1239	1382	870
	50+	2972	5275	2151
	Total HSDA:	4664	7124	3321
Total HA:		5215	7900	3762

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	12
	20-34	501	516	327
	35-49	1365	1517	968
	50+	3336	5854	2455
Total HA:		5215	7900	3762

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	602	963	442
Male	4611	6935	3320
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3762	55	650	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	242	189
	5 years or more	53	48
	<5 years	55	41
	Total HSDA:	350	278
RICHMOND	10 years or more	119	92
	5 years or more	34	28
	<5 years	48	43
	Total HSDA:	201	163
VANCOUVER	10 years or more	3218	2233
	5 years or more	841	611
	<5 years	605	477
	Total HSDA:	4664	3321
Total HA:		5215	3762

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3579	2514
	5 years or more	928	687
	<5 years	708	561
Total HA:		5215	3762

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	188	417	43	63
RICHMOND	45	311	9	95
VANCOUVER	673	11474	207	5401
Total:	906	12202	259	5559

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	77

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		360	521
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		126	176
SOUTH VANCOUVER ISLAND	20-34	74	80	53
	35-49	193	219	153
	50+	532	850	408
	Total HSDA:	799	1149	614
Total HA:		1285	1846	1000

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1285	1846	1000

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	221	320	168
Male	1064	1526	832

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1000	56	590	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	218	175
	5 years or more	82	59
	<5 years	60	50
	Total HSDA:	360	284
NORTH VANCOUVER ISLAND	10 years or more	84	69
	5 years or more	28	20
	<5 years	14	13
	Total HSDA:	126	102
SOUTH VANCOUVER ISLAND	10 years or more	478	345
	5 years or more	165	134
	<5 years	156	135
	Total HSDA:	799	614
Total HA:		1285	1000

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	780	589
	5 years or more	275	213
	<5 years	230	198
Total HA:		1285	1000

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	204	923	75	170
NORTH VANCOUVER ISLAND	157	279	39	69
SOUTH VANCOUVER ISLAND	221	1930	35	586
Total:	582	3132	149	825

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	109
NORTH VANCOUVER ISLAND	42
SOUTH VANCOUVER ISLAND	130
Total:	281

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	*
	35-49	15	18	*
	50+	28	36	*
	Total HSDA:	51	62	30
NORTH WEST	20-34	*	6	0
	35-49	*	38	18
	50+	*	75	38
	Total HSDA:	71	119	56
NORTHERN INTERIOR	0-19	6	6	*
	20-34	20	20	*
	35-49	58	75	*
	50+	114	194	*
	Total HSDA:	198	295	148
Total HA:		320	476	234

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	32	34	*
	35-49	97	131	*
	50+	185	305	*
Total HA:		320	476	234

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	176	81
Male	205	300	153

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	234	53	570	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	30	*
	5 years or more	6	*
	<5 years	15	*
	Total HSDA:	51	30
NORTH WEST	10 years or more	50	39
	5 years or more	11	10
	<5 years	10	7
	Total HSDA:	71	56
NORTHERN INTERIOR	10 years or more	103	82
	5 years or more	59	38
	<5 years	36	28
	Total HSDA:	198	148
Total HA:		320	234

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	183	136
	5 years or more	76	51
	<5 years	61	47
Total HA:		320	234

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	41	65	5	7
NORTH WEST	85	169	17	32
NORTHERN INTERIOR	122	498	21	189
Total:	248	732	43	228

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	5
NORTH WEST	19
NORTHERN INTERIOR	13
Total:	37

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	*
	KOOTENAY BOUNDARY	6	9	*
	OKANAGAN	30	50	*
	THOMPSON/CARIBOO/SHUSWAP	27	51	*
	Total HA:	68	121	49
FRASER	FRASER EAST	36	49	26
	FRASER NORTH	48	89	37
	FRASER SOUTH	83	119	58
	Total HA:	167	257	121
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	52	20
	RICHMOND	6	11	5
	VANCOUVER	464	908	372
	Total HA:	496	971	397
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	46	80	35
	NORTH VANCOUVER ISLAND	16	29	11
	SOUTH VANCOUVER ISLAND	49	96	38
	Total HA:	111	205	84
NORTHERN	NORTH EAST	9	13	5
	NORTH WEST	31	67	27
	NORTHERN INTERIOR	68	115	57
	Total HA:	108	195	89
Total:		950	1749	740

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	346	626	268
Male	604	1123	472

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	740	54	540	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.





Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





Monthly Report

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

